StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Oragenics Trading Down 6.6 %

Shares of OGEN opened at $0.34 on Tuesday. The company’s fifty day simple moving average is $0.39 and its 200 day simple moving average is $1.04. Oragenics has a 1-year low of $0.28 and a 1-year high of $7.74. The company has a market cap of $1.90 million, a price-to-earnings ratio of -0.05 and a beta of 0.49.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.